<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31427704</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test.</ArticleTitle><Pagination><StartPage>11970</StartPage><MedlinePgn>11970</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11970</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-48534-1</ELocationID><Abstract><AbstractText>In the endgame of global polio eradication, serosurveillance is essential to monitor each country's vulnerability to poliomyelitis outbreaks. Previously, we developed pseudovirus poliovirus (PV) neutralization test (pPNT) with type 1, 2, and 3 PV pseudovirus (PV<sub>pv</sub>), which possess a luciferase-encoding PV replicon in the capsids of wild-type strains (PV<sub>pv</sub>[WT]), showing that pPNT with type 2 and 3 PV<sub>pv</sub>(WT) but not type 1 shows high correlation with the conventional PV neutralization test (cPNT) performed with vaccine strains. Here, we analyse the antigenicity of PV<sub>pv</sub>(WT) and PV<sub>pv</sub> with capsid proteins of Sabin vaccine strains (PV<sub>pv</sub>[Sabin]) in human serum. Type 2 and 3 PV<sub>pv</sub>(WT) and PV<sub>pv</sub>(Sabin) show similar antigenicity in the analysed set of human sera in contrast to type 1 PV<sub>pv</sub>. The levels of PV<sub>pv</sub>(Sabin) infection (%), including about 70% of PV<sub>pv</sub> infection (%) measured in the presence of human serum diluted to the cPNT titre, serve as the optimal threshold values for pPNT (5% for type 1 and 2, 10% for type 3) to show high correlation with cPNT results. Our results suggest that pPNT with PV<sub>pv</sub>(Sabin) could serve as an alternative to cPNT and provide a rationale for pPNT threshold values.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arita</LastName><ForeName>Minetaro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3314-6626</Identifier><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo, 208-0011, Japan. minetaro@nih.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwai-Itamochi</LastName><ForeName>Masae</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu-shi, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000940" MajorTopicYN="N">Antigenic Variation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="Y">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31427704</ArticleId><ArticleId IdType="pmc">PMC6700111</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-48534-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-019-48534-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bodian D. Viremia in experimental poliomyelitis. I. General aspects of infection after intravascular inoculation with strains of high and of low invasiveness. Am. J. Hyg. 1954;60:339&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">13207104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodian D. Histopathologic basis of clinical findings in poliomyelitis. Am. J. Med. 1949;6:563&#x2013;578. doi: 10.1016/0002-9343(49)90130-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(49)90130-8</ArticleId><ArticleId IdType="pubmed">18119382</ArticleId></ArticleIdList></Reference><Reference><Citation>Couderc T, et al. Molecular pathogenesis of neural lesions induced by poliovirus type 1. J. Gen. Virol. 1989;70:2907&#x2013;2918. doi: 10.1099/0022-1317-70-11-2907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-70-11-2907</ArticleId><ArticleId IdType="pubmed">2555432</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Manual of laboratory methods for potency testing of vaccines used in the WHO Expanded Programme on Immunization. WHO publication no. WHO/BLG/95.1. World Health Organization, Geneva (1995).</Citation></Reference><Reference><Citation>Iwai Masae, Takizawa Takenori, Nakayama Takashi, Matsuura Kumiko, Yoshida Hiromu, Hasegawa Sumiyo, Obara Mayumi, Horimoto Eiji, Kurata Takeshi, Horie Hitoshi. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan. Scandinavian Journal of Infectious Diseases. 2008;40(3):247&#x2013;253. doi: 10.1080/00365540701596003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365540701596003</ArticleId><ArticleId IdType="pubmed">17907043</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34:1975&#x2013;1985. doi: 10.1016/j.vaccine.2014.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.11.015</ArticleId><ArticleId IdType="pubmed">25448090</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, et al. Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies. Trials Vaccinol. 2015;4:71&#x2013;74. doi: 10.1016/j.trivac.2015.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trivac.2015.08.001</ArticleId><ArticleId IdType="pmc">PMC4802416</ArticleId><ArticleId IdType="pubmed">27066157</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotta Chiemi, Ogawa Tomoko, Shirasawa Hiroshi. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine. Human Vaccines &amp; Immunotherapeutics. 2019;15(5):1154&#x2013;1159. doi: 10.1080/21645515.2019.1572408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1572408</ArticleId><ArticleId IdType="pmc">PMC6605838</ArticleId><ArticleId IdType="pubmed">30676843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama T, Suga S, Okada K, Okabe N. Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV) Jpn. J. Infect. Dis. 2019;72:49&#x2013;52. doi: 10.7883/yoken.JJID.2018.314.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2018.314</ArticleId><ArticleId IdType="pubmed">30381690</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh H, et al. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan. Vaccine. 2019;37:1964&#x2013;1971. doi: 10.1016/j.vaccine.2019.02.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.02.034</ArticleId><ArticleId IdType="pubmed">30827736</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAPIII_2014.pdf.</Citation></Reference><Reference><Citation>Arita M, Nagata N, Sata T, Miyamura T, Shimizu H. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J. Gen. Virol. 2006;87:3317&#x2013;3327. doi: 10.1099/vir.0.82172-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.82172-0</ArticleId><ArticleId IdType="pubmed">17030866</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Bigay J. Poliovirus Evolution toward Independence from the Phosphatidylinositol-4 Kinase III beta/Oxysterol-Binding Protein Family I Pathway. ACS Infect. Dis. 2019;5:962&#x2013;973. doi: 10.1021/acsinfecdis.9b00038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00038</ArticleId><ArticleId IdType="pubmed">30919621</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley EB, et al. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. J. Infect. Dis. 2018;217:371&#x2013;380. doi: 10.1093/infdis/jix556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix556</ArticleId><ArticleId IdType="pmc">PMC5853416</ArticleId><ArticleId IdType="pubmed">29304199</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimoin AW, et al. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection. J. Infect. Dis. 2018;217:223&#x2013;231. doi: 10.1093/infdis/jix584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix584</ArticleId><ArticleId IdType="pmc">PMC5853670</ArticleId><ArticleId IdType="pubmed">29253164</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushi S, et al. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J. Med. Virol. 2006;78:1509&#x2013;1512. doi: 10.1002/jmv.20732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20732</ArticleId><ArticleId IdType="pmc">PMC7166816</ArticleId><ArticleId IdType="pubmed">17063504</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Dong P, Kim Hyung G, Kim Young B, Poon Leo L.M, Cho Michael W. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology. 2004;326(1):140&#x2013;149. doi: 10.1016/j.virol.2004.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.05.017</ArticleId><ArticleId IdType="pmc">PMC7127165</ArticleId><ArticleId IdType="pubmed">15262502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright E., Temperton N. J., Marston D. A., McElhinney L. M., Fooks A. R., Weiss R. A. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. Journal of General Virology. 2008;89(9):2204&#x2013;2213. doi: 10.1099/vir.0.2008/000349-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/000349-0</ArticleId><ArticleId IdType="pmc">PMC2886951</ArticleId><ArticleId IdType="pubmed">18753230</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamin A, et al. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods. 2009;160:1&#x2013;6. doi: 10.1016/j.jviromet.2009.02.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2009.02.025</ArticleId><ArticleId IdType="pmc">PMC2704486</ArticleId><ArticleId IdType="pubmed">19559943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods. 2008;153:111&#x2013;119. doi: 10.1016/j.jviromet.2008.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2008.07.015</ArticleId><ArticleId IdType="pubmed">18722473</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Iwai M, Wakita T, Shimizu H. Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum. Clin. Vaccine Immunol. 2011;18:1889&#x2013;1894. doi: 10.1128/CVI.05225-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05225-11</ArticleId><ArticleId IdType="pmc">PMC3209023</ArticleId><ArticleId IdType="pubmed">21880850</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus. J. Med. Virol. 2017;89:2075&#x2013;2083. doi: 10.1002/jmv.24909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24909</ArticleId><ArticleId IdType="pubmed">28786502</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, et al. A simple and safe antibody neutralization assay based on polio pseudoviruses. Hum Vaccin Immunother. 2019;15:349&#x2013;357. doi: 10.1080/21645515.2018.1526553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1526553</ArticleId><ArticleId IdType="pmc">PMC6422504</ArticleId><ArticleId IdType="pubmed">30273512</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond DC, et al. Antigenic variation and resistance to neutralization in poliovirus type 1. Science. 1985;229:1090&#x2013;1093. doi: 10.1126/science.2412292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2412292</ArticleId><ArticleId IdType="pubmed">2412292</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel B, et al. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J. Virol. 1986;57:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC252701</ArticleId><ArticleId IdType="pubmed">2416957</ArticleId></ArticleIdList></Reference><Reference><Citation>Drexler JF, et al. Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proc. Natl. Acad. Sci. USA. 2014;111:12889&#x2013;12894. doi: 10.1073/pnas.1323502111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1323502111</ArticleId><ArticleId IdType="pmc">PMC4156724</ArticleId><ArticleId IdType="pubmed">25136105</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>